



TOLERABILITY OF RITUXIMAB CHOP (CYCLOPHOSPHAMIDE, HYDROXYDAUNORUBICIN, ONCOVIN AND PREDNISOLONE) REGIMEN FOR FOLLICULAR LYMPHOMA

Ann George*¹, Dawnji S.R² and Jayakumar K.L³

ARTICLE INFO

Article History:

Received 4th October, 2022
Received in revised form 25th November, 2022
Accepted 18th December, 2022
Published online 28th January, 2023

Key words:

adverse event; follicular lymphoma; non compliance; Rituximab; Rituximab-CHOP regimen; tolerability.

ABSTRACT

Background and Objective: Many clinical trials conducted in the western population have shown that the addition of Rituximab to CHOP regimen provided a higher response rate and excellent early survival in follicular lymphoma. This study aimed to assess the tolerability to Rituximab-CHOP regimen for Follicular lymphoma in Indian population. **Methods:** From January 2015 to January 2016, 32 patients with histopathologically proven denovo follicular lymphoma who were prescribed. Rituximab-CHOP regimen once every 21 days for 6-8 cycles were included in the study. Adverse events causing non compliance to chemotherapy schedule were studied. Causality assessment and grading of severity were done for the above adverse events. **Results and Discussion:** Age range of the study population was from 37-83 years. 78.125% patients were males. Most of the patients belonged to Ann Arbor Stage III/IV. Adverse events causing noncompliance included Infusion related reaction in two patients which was certainly related to Rituximab with a toxicity grade 3 and febrile neutropenia (possibly caused by Doxorubicin with toxicity grade 3), leukopenia (possibly caused by Doxorubicin or Vincristine with a toxicity grade 2) and pancytopenia (possibly caused by Cyclophosphamide or Doxorubicin or Vincristine with a toxicity grade of 3) in one patient each. **Conclusion:** Adverse drug reactions caused by Rituximab and possibly by Doxorubicin, Vincristine or Cyclophosphamide were a reason for non compliance.

Copyright © The author(s) 2023. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Lymphomas make up 3-4% of all cancers, making them the seventh-most common form¹. Non-Hodgkin's lymphomas (NHL) are neoplastic transformations of mature B, T and natural killer (NK) cells. Follicular lymphoma (FL) is the most common indolent lymphoma and the second most common non-Hodgkin lymphoma^{2,3}. NHL infiltrates lymphohematopoietic tissues and are among the most sensitive malignancies to radiation and cytotoxic therapy. Rituximab-CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisolone) regimen is a chemotherapy regimen for follicular lymphoma. The rationale behind conducting this study is to obtain reliable data regarding response and tolerability of Rituximab-CHOP regimen for follicular lymphoma in Kerala population.

AIM

A prospective single arm observational study on the tolerability of patients to Rituximab CHOP regimen for follicular lymphoma given in a tertiary care setting

OBJECTIVE

To study the tolerability of patients to Rituximab CHOP regimen for follicular lymphoma

Study Design and Setting

A prospective single arm observational study in the Department of Radiotherapy, Medical College,

Thiruvananthapuram, with 32 consecutive patients diagnosed by histopathology to have de novo follicular lymphoma and planned to be started on Rituximab -CHOP regimen, from the date of Ethical clearance (09/01/2015), for a period of one year (IEC No: 01/33/2015/MCT)

MATERIALS AND METHODS

Selection and description of participants

Study Design: Prospective single arm observational study.

Study Setting: Department of Radiotherapy, Government Medical College, Thiruvananthapuram.

Study Period: January 2015 to January 2016.

Study Population: Patients with histopathologically proven denovo follicular lymphoma who are prescribed R-CHOP regimen.

Sample Size: Thirty two

Sample size calculation: The response rate to Rituximab CHOP regimen among patients with follicular lymphoma is 75%⁴.

This finding is used to calculate the sample size of the current study.

Sample size, $n = (t \alpha/z)^2 pq / d^2$

Response rate, $p = 75\%$ Precision, $d = 20\%$ of p Significance level = 5% $n = 32$

*Corresponding author: Ann George
Apollo Hospitals, Hyderabad

Sampling technique: Consecutive patients attending Radiotherapy OPD, diagnosed to have follicular lymphoma and started on Rituximab CHOP regimen.

Inclusion criteria

- Patients with histopathologically proven denovo follicular lymphoma started on Rituximab CHOP regimen who have not received any other disease specific treatment.
- Patients who give informed consent.
- Age above 18 years.
- Both males and females.
- Exclusion criteria:
- Pregnancy and breast feeding patients.

Technical information

Study tools

1. Chemotherapy Protocol
2. Semi structured questionnaire
3. Revised response criteria for malignant lymphoma
4. Informed consent form - English and Malayalam
5. FLIPI (Follicular Lymphoma International Prognostic Index)

Study procedure

Rituximab CHOP regimen is given in the Department of Radiotherapy, Government Medical College, Thiruvananthapuram on an outpatient basis once every 21 days for 6 - 8 cycles. Patients satisfying inclusion criteria were enrolled into the study until the required sample size was attained. A total of two visits were done per patient. During the first visit, after obtaining informed consent, semi structured questionnaire and chemotherapy protocol were filled. Adherence to the chemotherapy schedule was enquired by telephonic interview with the patient on the day prior to each cycle. The second visit to the patient was on the day of the last cycle, when compliance was assessed, by comparing initial schedule with the schedule undergone. If an adverse event was found to have caused noncompliance, WHO - UMC Causality assessment system was used. NCI toxicity criteria were then used to grade the severity of those events.

Tolerability refers to the degree to which side effects of a drug are tolerated by a patient. Non compliance percentage due to adverse events is a measure of tolerability in this study. Rituximab-CHOP Regimen (Rituximab - Cyclophosphamide, Hydroxydaunorubicin, Oncovin and Prednisolone) with adjuvant medications : 1) Inj. Ondansetron 8mg IV single dose 2) Inj. Paracetamol 1g IM single dose 30 minutes prior to Rituximab 3) Inj. Pheniramine maleate 25mg single IV bolus 30 minutes prior to Rituximab 4) Inj. Dexamethasone 16mg single IV bolus 30 mins prior to Rituximab 5) T. Prednisolone 20mg 3-0-2 for 5 days. First dose given 30 mins prior to Rituximab 6) Inj. Rituximab 375mg/m² IV infusion in 500ml 0.9% NaCl 7) Inj. Cyclophosphamide 750mg/m² IV bolus Methodology 34 8) Inj. Doxorubicin 50mg/m² IV infusion over 30 minutes 9) Inj. Vincristine 1.4mg/m² IV over 5 - 10 minutes 10) Inj. Ranitidine 50mg IV single dose 11) . T. Allopurinol 300mg oral od for 1-2 cycles 12) T. Pantoprazole 40mg bd for 10 days 13) T. Ondansetron 8mg tds for 8 days

STATISTICS

Data is analysed using descriptive statistics (proportions and percentages).

RESULTS

The present study was conducted in the department of Radiotherapy, Government Medical College, Trivandrum between January 2015 and January 2016 in thirty two patients with the diagnosis of histopathologically proven de novo follicular lymphoma. They were prescribed Rituximab-CHOP regimen. Patients who were adequately staged and who have not received any other disease specific treatment were included in the study. Adverse events causing non compliance included infusion related reaction and abnormal peripheral blood cell counts.

Stage Wise Distribution of Study Subjects

Follicular lymphoma is staged based on Ann Arbor staging system adapted for Non Hodgkin’s lymphoma .Majority of patients belonged to stage III or IV as given in table-1.

Table 1 showing number of patients belonging to each stage of follicular lymphoma.

stage	Frequency	Percentage
I	0	0
II	4	12.5
III	18	56.25
IV	10	31.25
total	32	100

Distribution of CD Positivity among Study Subjects

All patients included in this study were CD 20 positive by immunohistochemistry.

Categorisation of Study Subjects Based on Compliance to Chemotherapy Schedule

Patients who followed the chemotherapy schedule dates were categorized as compliant and others were categorized as non compliant. Twenty five patients were compliant while seven patients were non compliant.

Non compliance due to adverse events

Reason for non compliance was adverse event for five patients while two patients were non compliant due to other reasons. Tolerability refers to the degree to which side effects of a drug are tolerated by a patient. Non compliance percentage due to adverse events is a measure of tolerability in this study. 15.625% of patients in this study didn’t tolerate this regimen due to adverse events.

Adverse events causing non compliance

As given in table 2, out of the thirty two patients studied, five were non compliant due to adverse events. Adverse events which led to non compliance to chemotherapy schedule included infusion related reaction in two patients ; febrile neutropenia, decreased white blood cell count and pancytopenia in one patient each. Infusion related reaction occurred during third and fourth cycles for two patients. In both the patients CHOP was given on day 1 and Rituximab was given on day 2 of each cycle .The reaction occurred first during the third infusion of Rituximab and repeated during fourth infusion of Rituximab .So, there is plausible time relation for reaction with Rituximab infusion and rechallenge data is satisfactory. Hence infusion related reaction is considered to be certainly due to Rituximab. The adverse event is graded 3 according to NCI toxicity grading criteria CTCAE version 4 as the reaction didnt respond promptly to symptomatic medication and prolonged hospital stay. Febrile

neutropenia was possibly caused by Doxorubicin. Leukopenia can be caused by Doxorubicin or Vincristine. Cyclophosphamide, Doxorubicin or Vincristine can cause pancytopenia. 90 Patient who developed febrile neutropenia had absolute neutrophil count of 980/mm³ and body temperature > 101.0 F, hence grade 3. Patient who developed leucopenia had WBC count of 2100/mm³, hence grade 2 toxicity. Patient who developed pancytopenia required hospitalization and had limitation of ADL, hence grade 3 toxicity according to NCI toxicity grading criteria CTCAE version 4.

Table 2 showing Adverse events, their causality assessment and grading

Patient identification number	CT cycle number	Adverse event	Suspected drugs	WHO causality category	NCI grade
1	3,4	Infusion related reaction	Rituximab	Certain	3
3	3,4	Infusion related reaction	Rituximab	Certain	3
8	2	Febrile neutropenia	Doxorubicin	Possible	3
10	3	White blood cell decreased	Doxorubicin, Vincristine	Possible	2
31	2	Pancytopenia	Cyclophosphamide, Doxorubicin, Vincristine,	Possible	3

DISCUSSION

Rituximab CHOP regimen has the highest efficacy ever described with any chemotherapy in follicular lymphoma⁵. Addition of Rituximab to chemotherapy has made significant improvements in response rate and progression free survival of patients with follicular lymphoma⁶⁻⁸. This study was undertaken to study the response of follicular lymphoma to R-CHOP regimen. Secondary objective was to assess the tolerability of patients to this regimen by listing the adverse events leading to non compliance to R-CHOP regimen followed by causality assessment and grading of toxicity. According to FLIPI, patients with age less than 60 years have better prognosis when compared to those with age greater than 60 years. In the present study, 24 patients were less than 60 years and 8 patients were more than 60 years of age. Age range of patients included in this study was from 37 to 83 years which is same as that in a study by M.J. Overman *et al*⁹. FL has slight female preponderance^{10,11}. The present study included 25 males and 7 females. In this study, 87.5% patients had stage III or IV disease compared to a study by M.J.Overman *et al* which had 80 % patients with stage III or IV disease⁹. All patients in this study were CD 20 positive by immunohistochemistry, as in a study by Myron S. Czuczman *et al*¹². In this study, according to FLIPI score, 16% patients were low risk, 31% intermediate risk and 53% high risk. In a study by Samuel A. Jacobs *et al*, the corresponding figures were 25%, 33% and 42%.¹³ In the present study, CR rate after R CHOP was 40.625%. In a study by Samuel A.Jacobs *et al*, complete response rate was 40%.¹³

Limitations of the study-This study was a prospective observational study. For better assessment of efficacy, a randomized controlled trial is preferable. Sample size was small. Larger sample size will yield a better picture of FL in Indian population.

References

- Marcus, Robert (2013). Lymphoma: pathology, diagnosis and treatment (Second ed.). p. 1.
- Muller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution and etiology. *Ann Hematol* 2005; 84:1-12.
- Tan DE, Foo JN, Bei JX *et al*. Genome-wide association study of B-cell non- Hodgkin's lymphoma identifies 3q27 as a susceptibility locus in the Chinese population. *Nat Genet* 2013; 4:804-7
- Eva Domingo-Domènech, Eva González-Barca, Cristina Estany, Alberto Fernández de Sevilla Combined treatment with anti CD20 and CHOP in relapsed advanced stage follicular lymphomas. *Haematologica* 2002 Nov; 87(11):1229-30.
- Coiffier B. Rituximab therapy in malignant lymphoma. *Oncogene*. 2007 May 28; 26(25):3603-13.
- van Oers MH, Klasa R, Marcus RE *et al*. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. *Blood* 2006; 108: 3295-3301
- Salles G, Mounier R, de Guibert S *et al*. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. *Blood* 2008; 112: 4824-4831.
- vanOers MH, Van Glabbeke M, Baila L *et al*. EORTC 20981 Intergroup Study. Rituximab in remission induction and maintenance treatment of relapsed follicular NHL: a phase III randomized clinical trial. Updated analysis of maintenance 2008. American Society of Hematology 2009 Annual Meeting (Abstr 838).
- J. Overman, L. Feng, B. Pro, P. McLaughlin, M. Hess, F. Samaniego. The addition of rituximab to CHOP chemotherapy improves Bibliography 60 overall and failure-free survival for follicular grade 3 lymphoma. *Annals of Oncology* 19: 553-559, 2008 doi:10.1093/annonc/mdm511 Published online 13 December 2007.
- Armitage JO, Weisenburger DD. New approach to classifying nonHodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J ClinOncol* 1998; 16:2780-2795.
- Harris NL, Jaffe ES, Diebold J, *et al*. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. *J ClinOncol* 1999; 17:3835-3849.
- Myron S. Czuczman, Robin Weaver, BahaAlkuzweny, Judy Berlfein, and Antonio J. Grillo-Lopez Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin's Lymphoma

Treated With Rituximab Plus CHOP Chemotherapy: 9-
Year Follow up- DOI: 10.1200/JCO.2004.04.020

13. Samuel A. Jacobs *et al* Phase II trial of short course
RCHOP followed by 90Y-ibrutumomab tiuxetan and
extended Rituximab in previously untreated follicular
lymphoma Clin Cancer Res November 1 2008 14 (21)
7088- 7094; DOI:10.1158/1078-0432.CCR-08-0529
